MAX Chat
Company Analysis Ampio Pharmaceuticals, Inc.
1. Summary
Advantages
- Price (0.0029 $) is less than fair price (0.007 $)
- Current debt level 4.78% is below 100% and has decreased over 5 years from 10.71%.
Disadvantages
- Dividends (0%) are below the sector average (1.29%).
- The stock's return over the last year (-73%) is lower than the sector average (-48.5%).
- The company's current efficiency (ROE=-256.9%) is lower than the sector average (ROE=-70.06%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Ampio Pharmaceuticals, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | -6.9% | -5.9% | 2% |
| 90 days | -97.7% | -42.2% | 9.8% |
| 1 year | -73% | -48.5% | 17.3% |
AMPE vs Sector: Ampio Pharmaceuticals, Inc. has significantly underperformed the "Healthcare" sector by -24.5% over the past year.
AMPE vs Market: Ampio Pharmaceuticals, Inc. has significantly underperformed the market by -90.31% over the past year.
Slightly volatile price: AMPE is more volatile than the rest of the market on "New York Stock Exchange" over the last 3 months, with typical deviations of about +/- 5-15% per week.
Long period: AMPE with weekly volatility of -1.4% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (0.0029 $) is lower than the fair price (0.007 $).
Price significantly below the fair price: The current price (0.0029 $) is 141.4% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (27.78).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (50.97).
4.3. P/BV
P/BV vs Sector: The company's P/BV (0.4629) is lower than that of the sector as a whole (10.53).
P/BV vs Market: The company's P/BV (0.4629) is lower than that of the market as a whole (18.11).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (0) is lower than that of the sector as a whole (4.07).
P/S vs Market: The company's P/S indicator (0) is lower than that of the market as a whole (27.96).
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (0.2438) is lower than that of the sector as a whole (18.1).
EV/Ebitda vs Market: The company's EV/Ebitda (0.2438) is lower than that of the market as a whole (39.19).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -9.54% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-9.54%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (1364.64%).
5.4. ROE
ROE vs Sector: The company's ROE (-256.9%) is lower than that of the sector as a whole (-70.06%).
ROE vs Market: The company's ROE (-256.9%) is lower than that of the market as a whole (34.58%).
5.5. ROA
ROA vs Sector: The company's ROA (-150.49%) is lower than that of the sector as a whole (8.48%).
ROA vs Market: The company's ROA (-150.49%) is lower than that of the market as a whole (11.54%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (21.56%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (10.02%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '1.29%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
